Increased atherogenicity of low-density lipoprotein in heavy proteinuria

Nephrology Dialysis Transplantation

Volumn 13, Issue 5, 1998, Pages 1183-1188

  Deighan, Christopher J ^a   Caslake, Muriel J ^a   McConnell, Michael ^a   Boulton Jones, J Michael ^a   Packard, Christopher J ^a  

^a NHS GREATER GLASGOW AND CLYDE   (United Kingdom)

Author keywords

Cardiovascular risk; Glomerulonephritis; LDL subfractions; Lipoprotein metabolism; Low density lipoprotein; Proteinuria

Indexed keywords

APOLIPOPROTEIN E; LIPOPROTEIN LIPASE; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR; VERY LOW DENSITY LIPOPROTEIN;

ADULT; ARTICLE; ATHEROGENESIS; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CONTROLLED STUDY; DENSITY GRADIENT CENTRIFUGATION; FEMALE; GLOMERULOPATHY; HUMAN; LIPOPROTEIN METABOLISM; MALE; PARTICLE SIZE; PRIORITY JOURNAL; PROTEINURIA;

ADULT; AGED; ANTHROPOMETRY; APOLIPOPROTEINS E; ARTERIOSCLEROSIS; FEMALE; HUMANS; KIDNEY; LIPASE; LIPIDS; LIPOPROTEINS; LIPOPROTEINS, LDL; LIPOPROTEINS, VLDL; MALE; MIDDLE AGED; PHENOTYPE; PROTEINURIA;

EID: 0031970297     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/13.5.1183     Document Type: Article

References (30)

1. Epstein AA. The nature and treatment of chronic parenchymal nephritis (nephrosis). JAMA 1917; 235: 444-447
2. Ordonez JD, Hiatt RA, Killebrew EJ, Fireman BH. The increased risk of coronary heart disease associated with the nephrotic syndrome. Kidney Int 1993; 44: 638-642
3. Baxter JH, Goodman HC, Havel RJ. Serum lipid and lipoprotein abnormalities in nephrosis. J Clin Invest 1960; 39: 455-465
4. Warwick GL, Packard CJ, Demant T, Bedford DK, Boulton-Jones JM, Shepherd J. Metabolism of apolipoprotein B-containing lipoprotein in subjects with nephrotic range proteinuria. Kidney Int 1991; 40: 129-138
5. Warwick GL, Packard CJ. Lipoprotein metabolism in the nephrotic syndrome Nephrol Dial Transplant 1993; 8: 385-396
6. Joven J, Villabona C, Vilella E, Masana L, Alberti R, Valles M. Abnormalities of lipoprotein metabolism in patients with nephrotic syndrome. N Engl J Med 1990; 323: 579-584
7. Joven J, Rubies-Prat J, Espinel E, Ras MR, Piera L. High density lipoproteins in untreated idiopathic nephrotic syndrome without renal failure. Nephrol Dial Transplant 1987; 2: 149-153
8. Chan MK, Varghese Z, Persaud J, Moorhead JF. Post-heparin hepatic and lipoprotein lipase activities in nephrotic syndrome. Aust NZ Med J 1984; 14: 841-847
9. Warwick GL, Packard CJ, Stewart JP et al. Post prandial lipoprotein metabolism in the nephrotic syndrome. Eur J Clin Invest 1992; 22: 813-820
10. Austin MA, King MC, Vranigan KM, Krauss RM. Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. Circulation 1990; 82: 495-506
11. Krauss RM. Heterogeneity of plasma low-density lipoproteins and atherosclerosis risk. Curr Opin Lipidol 1994; 5: 339-349
12. Griffin BA, Freeman DJ, Tait GW et al. Role of plasma triglyceride in the regulation of plasma low-density lipoprotein (LDL) subfractions: relative contribution of small, dense LDL to coronary heart disease. Atherosclerosis 1994; 106: 241-253
13. Stampfer MJ, Krauss RM, Ma J et al. A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. JAMA 1996; 276: 882-888
14. Gardner CD, Fortmann SP, Krauss RM. Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women. JAMA 1996; 276: 875-881
15. Packard CJ. Plasma triglycerides, LDL heterogeneity and atherogenesis. Therapy Express 1994; 85: 1-6
16. Neugarten J, Schlondorff D. Lipoprotein interactions with glomerular cells and matrix. In: Keane WF, Stein JH, eds. Lipids and Renal Disease. Churchill Livingstone, New York, 1992; 173-206
17. Coritsidis G, Rifici V, Gupta S et al. Preferential uptake of oxidised LDL to rat glomeruli in vivo and cultured mesangial cells in vitro. Kidney Int 1991; 39: 858-866
18. Lerique B, Moulin B, Delpero C, Purgus R, Olmer M, Boyer J. Apolipoprotein E phenotype and hyperlipoproteinemia in nephrotic syndrome. Clin Chem 1994; 40: 849-850
19. Watson TDG, Burns L, Packard CJ, Shepherd J. Selective determination of lipoprotein lipase and hepatic lipase in heparinised plasma from horses. Am J Vet Res 1992; 53: 771-775
20. Lipid Research Clinic's Program. Manual of Laboratory Operations I: Lipid and Lipoprotein Analysis. National Institutes of Health, Bethesda Md, 1975, 75. US Dept of Health, Education, and Welfare publication NIH 75-628
21. Griffin BA, Caslake MJ, Yip B, Tait GW, Packard CJ, Shepherd J. Rapid isolation of low density lipoprotein (LDL) subfractions from plasma by density gradient ultracentrifugation. Atherosclerosis 1990; 83: 59-67
22. Havekes LM, de Knijff, Beisegel U, Havinga J, Smit M, Klasen E. A rapid micromethod for apolipoprotein E phenotyping directly in serum. J Lipid Res 1987; 28: 455-463
23. Tan CE, Forster L, Caslake MJ et al. Relations between plasma lipids and post heparin lipases and VLDL and LDL subfractions in normolipaemic men and women. Arterioscler Thromb Vasc Biol 1995; 15(11): 1839-1848
24. Appel GB, Blum CB, Chien S, Kunis CL, Appel AS. The hyperlipidemia of the nephrotic syndrome: relation to plasma albumin concentration, oncotic pressure and viscosity. N Engl J Med 1985; 312: 1544-1548
25. Joven J, Espinel E, Simo J, Vilella E, Camps J, Oliver A. The influence of hypoalbuminaemia in the generation of nephrotic hyperlipidaemia. Atherosclerosis 1996; 126: 243-252
26. Packard CJ, Shepherd J. Metabolic basis of the link between triglycerides and coronary heart disease. In: Guftavrborn VR, Colin J, Schwartz J, ed. New Horizons in Coronary Heart Disease. Current Science, London, 1993; 4.1-4.11
27. Kashyap ML, Srivasta LS, Hynd BA et al. Apolipoprotein CII and lipoprotein lipase in human nephrotic syndrome. Atherosclerosis 1980; 35: 29-40
28. O'Neal D, Lee P, Murphy B, Best J. Low-density lipoprotein particle size distribution in end-stage renal disease treated with hemodialysis or peritoneal dialysis. Am J Kidney Dis 1996; 27: 84-91
29. Joven J, Vilella E, Ahmad S, Cheung M, Brunzell JD. Lipoprotein heterogeneity in end-stage renal disease. Kidney Int 1993; 43: 410-418
30. MacTier R, Boulton-Jones JM, Payton CD, McLay A. The natural history of membranous nephropathy in the West of Scotland. Q J Med 1986; 232: 793-802